Should You Buy Chemomab Therapeutics Ltd - ADR (CMMB) in Biotechnology Industry?

Chemomab Therapeutics Ltd - ADR (CMMB) is around the middle of the Biotechnology industry according to InvestorsObserver. CMMB received an overall rating of 40, which means that it scores higher than 40 percent of all stocks. Chemomab Therapeutics Ltd - ADR also achieved a score of 39 in the Biotechnology industry, putting it above 39 percent of Biotechnology stocks. Biotechnology is ranked 50 out of the 148 industries.

CMMB has an Overall Score of 40. Find out what this means to you and get the rest of the rankings on CMMB!

See Full CMMB Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 40 means the stock is more attractive than 40 percent of stocks. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Chemomab Therapeutics Ltd - ADR Stock Today?

Chemomab Therapeutics Ltd - ADR (CMMB) stock is trading at $1.68 as of 11:43 AM on Thursday, Feb 23, a loss of -$0.33, or -16.21% from the previous closing price of $2.01. The stock has traded between $1.55 and $1.92 so far today. Volume today is low. So far 603,756 shares have traded compared to average volume of 916,358 shares. Click Here to get the full Stock Report for Chemomab Therapeutics Ltd - ADR stock.